Bioaxial secures €1.9m funding to
develop fluorescence microscopy instruments
4 December 2013
Paris-based Bioaxial has completed a €1.9 million (US$2.7m)
equity investment by three new large investors. This capital will back the commercial launch of Bioaxial’s first
product, an optical microscopy module.
The capital, which comes from specialized funds for seed
investment in young startups, is provided by Amorcage Technologique Investissement
(a fund managed by CEA Investissement), Inserm Transfert Initiative
and Viveris Management, plus a range of individual investors. The
microscopy module is expected in the
second half of 2014.
Bioaxial is developing imaging instruments for
fluorescence microscopy that allow extended imaging of live cells
with an improved resolution so far unreachable in research
laboratories. This innovative module not only allows observation of
living cells in super-resolution over time without damaging them,
but unlike its competitors, does not require complex manipulations.
It has been tested at the Institut Pasteur for the last 12 months.
The founders of Bioaxial are experts in the industrialization of
innovation and have an international track record in the
semiconductor and optics industries.
“The investment of funds in Bioaxial’s capital is a vote of
confidence in the team and its technology. It is a strong signal for
the targeted market segment. It brings us credibility and allows us
to launch commercially,” said Louis Philippe Braitbart, CEO and
co-founder of Bioaxial.
“Our technology revolutionizes optical microscopy in the life
sciences market,” said Gabriel Sirat, CTO, co-founder and inventor
of the technology. “We expect applications in many areas where
improved resolution is essential to better understand the processes
of live entities.”
“We enthusiastically support Bioaxial in the commercial launch of
its first product. Their technological breakthrough delivers strong
differentiation to its first range of instruments,” said Celia Hart,
investment director at CEA Investissement. “The key gains are in
terms of resolution, the ability to image live cells, ease of use
and in cost. The management team also has extensive experience in
the development of instruments all the way to the market.”
“This is our second investment in medical device
instrumentation,” said Matthieu Coutet, managing director at Inserm
Transfert Initiative. “We were very impressed by this ambitious
project, which brings together an experienced team, a disruptive
technology and clearly identified business opportunities.”